VEA
MREO

Virtus ETF Advisers’s Mereo BioPharma MREO Stock Holding History

Virtus ETF Advisers’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,060
Closed -$66.7K – 648
2024
Q4 		$66.7K Buy
+19,060
New +$74.9K 0.03% 403

Other funds holding MREO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Virtus ETF Advisers's MREO Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Mereo BioPharma (MREO) in Q1 2025, closing a stake of 19,060 shares — an estimated $66.7K sold.

Virtus ETF Advisers first reported a position in MREO in Q4 2024 and held it in 1 quarter. The position peaked at $66.7K in Q4 2024. 90 funds tracked by Wall St. Rank hold MREO as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Mereo BioPharma position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 19,060 Mereo BioPharma shares in Q1 2025, an estimated $66.7K.
  • Virtus ETF Advisers first reported a position in Mereo BioPharma in Q4 2024 and held it in 1 quarter.
  • Virtus ETF Advisers's Mereo BioPharma position peaked at $66.7K in Q4 2024.
  • 90 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.